CD19
CD19, also known as B4 or CVID3, is a membrane immunoglobulin that is expressed on follicular dendritic cells and B cells. It contains two Ig-like C2-type domains in the extracellular portion while the cytoplasmic portion undergoes phosphorylation upon the recipient of different cellular signals. CD19 is involved in the B cell response to antigens. It is a low-affinity antigen receptor that is crucial for the decreasing of the threshold for antigen receptor-dependent stimulation. CD19 is often associated with CD21, CD81, CD82, VAVA2, and Complement receptor 2 for its biological function. Defects in CD19 are the main cause of immunodeficiency common variable type 3 (CVID3), or antibody deficiency, a disorder that is characterized by poor B-cell differentiation and impaired antibody production.
CD19 is a biomarker for B-cell lymphomas. It is now under evaluation as a target for antibody-based immunotherapies against B-cell lymphomas as well as some autoimmune diseases.
Entrez Gene ID: 930
UniProt ID: P15391
Related Services:
Loading...
| Catalog | Product name | Similar to | Antibody | Linker | Payload | Data sheet | Inquiry |
| ADC-W-119 | Anti-CD19 (clone hBU12)-vc-PAB-MMAE ADC | Anti-CD19-antibody | VC-PAB (valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE (Monomethyl auristatin E) |
|
Inquiry | |
| ADC-W-155 | Anti-CD19 (clone BU12)-Mc-MMAF ADC | Humanized Anti-CD19 antibody, clone # BU12 | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
|
Inquiry | |
ADC-W-322  |
Anti-CD19 (clone hBU12)-Mc-MMAF ADC | SGN-CD19A | Anti-CD19 antibody, clone # Hbu12 | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
|
Inquiry |
| ADC-W-323 | Anti-CD19 (clone hBU12)-Mc-MMAE ADC | Humanized Anti-CD19 lgG1κ antibody, clone # Hbu12 | Mc (maleimidocaproyl) | MMAE (Monomethyl auristatin E) |
|
Inquiry | |
| ADC-W-324 |
Anti-CD19 (clone huB4)-SPDB-DM4 ADC | SAR3419 | Humanized Anti-CD19 lgG1κ antibody, clone # huB4 | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) |
|
Inquiry |
| ADC-W-493 |
Anti-CD19 (clone huB4)-Mc-MMAF ADC | SGN-CD19A(Denintuzumab mafodotin) | Humanized Anti-CD19 lgG1 Antibody, huB4 | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
|
Inquiry |
| ADC-W-589 | Anti-CD19 (clone huB4)-SMCC-DM1 ADC | Humanized Anti-CD19 lgG1 Antibody | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) |
|
Inquiry | |
| ADC-W-595 | Anti-CD19 (MDX1435)-VC-duocarmycin ADC | Human Anti-CD19 Antibody, MDX1435 | VC (valine-citrulline) | duocarmycin |
|
Inquiry | |
| ADC-W-613 | Anti-CD19 (B496)-SPP-DM1 ADC | Anti-CD19 IgG1 Antibody, B496 | SPP (N-succinimidyl-4-(2-pyridyldithio)pentanoate) | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) |
|
Inquiry | |
| ADC-W-614 | Anti-CD19 (B496)-MCC-DM1 ADC | Anti-CD19 IgG1 Antibody, B496 | MCC (Maleimidomethyl cyclohexane-1-carboxylate) | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) |
|
Inquiry | |
| ADC-W-615 | Anti-CD19 (B496)-Mc-VC-PABC-MMAE ADC | Anti-CD19 IgG1 Antibody, B496 | MC-VC-PABC (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE (Monomethyl auristatin E) |
|
Inquiry | |
| ADC-W-616 | Anti-CD19 (B496)-Mc-MMAF ADC | Anti-CD19 IgG1 Antibody, B496 | MC-VC-PABC (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAF (Monomethyl auristatin F) |
|
Inquiry | |
| ADC-W-770 | Anti-CD19 (Taplitumomab paptox)-SMCC-DM1 ADC | Anti-CD19 IgG1-kappa antibody, Taplitumomab paptox | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine) |
|
Inquiry | |
| ADC-W-771 | Anti-CD19 (Taplitumomab paptox)-SPDB-DM4 ADC | Anti-CD19 IgG1-kappa antibody, Taplitumomab paptox | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) |
|
Inquiry | |
| ADC-W-772 | Anti-CD19 (Taplitumomab paptox)-MC-MMAF ADC | Anti-CD19 IgG1-kappa antibody, Taplitumomab paptox | MC (maleimidocaproyl) | MMAF |
|
Inquiry | |
| ADC-W-773 | Anti-CD19 (Taplitumomab paptox)-MC-Vc-PAB-MMAE ADC | Anti-CD19 IgG1-kappa antibody, Taplitumomab paptox | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
|
Inquiry | |
| ADC-W-774 | Anti-CD19 (Taplitumomab paptox)-MC-Vc-PAB-SN38 ADC | Anti-CD19 IgG1-kappa antibody, Taplitumomab paptox | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
|
Inquiry | |
| ADC-W-775 | Anti-CD19 (Taplitumomab paptox)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | Anti-CD19 IgG1-kappa antibody, Taplitumomab paptox | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
|
Inquiry | |
| ADC-W-776 | Anti-CD19 (Blinatumomab)-SMCC-DM1 ADC | Anti-CD19 (scFv-kappa-heavy)-(scFv-heavy-kappa) antibody, Blinatumomab | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine) |
|
Inquiry | |
| ADC-W-777 | Anti-CD19 (Blinatumomab)-SPDB-DM4 ADC | Anti-CD19 (scFv-kappa-heavy)-(scFv-heavy-kappa) antibody, Blinatumomab | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) |
|
Inquiry | |
| ADC-W-778 | Anti-CD19 (Blinatumomab)-MC-MMAF ADC | Anti-CD19 (scFv-kappa-heavy)-(scFv-heavy-kappa) antibody, Blinatumomab | MC (maleimidocaproyl) | MMAF |
|
Inquiry | |
| ADC-W-779 | Anti-CD19 (Blinatumomab)-MC-Vc-PAB-MMAE ADC | Anti-CD19 (scFv-kappa-heavy)-(scFv-heavy-kappa) antibody, Blinatumomab | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
|
Inquiry | |
| ADC-W-780 | Anti-CD19 (Blinatumomab)-MC-Vc-PAB-SN38 ADC | Anti-CD19 (scFv-kappa-heavy)-(scFv-heavy-kappa) antibody, Blinatumomab | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
|
Inquiry | |
| ADC-W-781 | Anti-CD19 (Blinatumomab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | Anti-CD19 (scFv-kappa-heavy)-(scFv-heavy-kappa) antibody, Blinatumomab | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
|
Inquiry | |
| ADC-W-2516 | Anti-CD19 (Denintuzumab)-SMCC-DM1 ADC | Humanized Anti-CD19 IgG1-kappa antibody, Denintuzumab | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine) |
|
Inquiry | |
| ADC-W-2517 | Anti-CD19 (Denintuzumab)-SPDB-DM4 ADC | Humanized Anti-CD19 IgG1-kappa antibody, Denintuzumab | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) |
|
Inquiry | |
| ADC-W-2518 | Anti-CD19 (Denintuzumab)-MC-Vc-PAB-MMAE ADC | Humanized Anti-CD19 IgG1-kappa antibody, Denintuzumab | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
|
Inquiry | |
| ADC-W-2519 | Anti-CD19 (Denintuzumab)-MC-Vc-PAB-SN38 ADC | Humanized Anti-CD19 IgG1-kappa antibody, Denintuzumab | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
|
Inquiry | |
| ADC-W-2520 | Anti-CD19 (Denintuzumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | Humanized Anti-CD19 IgG1-kappa antibody, Denintuzumab | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
|
Inquiry |
If you can’t find your product on this list? Please directly send email to info@creative-biolabs.com
For Research Use Only. NOT FOR CLINICAL USE.
Online Inquiry
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.
